Cai Junchao, Terasaki Paul I
Terasaki Foundation Laboratory, USA.
Clin Transpl. 2004:331-44.
The limited availability of donated hearts is not sufficient to meet the needs of increasing numbers of heart transplant candidates. Thus, it is important to find the best recipient for each donated heart in order to achieve the best graft and patient survival. We investigated heart transplant outcomes in the US and the factors that influence them. We present information regarding 36,277 heart transplants reported to the OPTN/ UNOS Registry from January 1988-October 2004. The annual number of transplants ranged between 2,057-2,363 during the past 14 years and has not increased since 1990. One- and 5-year graft survival rates have gradually increased and have reached 87% and 72%, respectively, for adult recipients. Non-immunological factors, such as the circumstance of the donor's death, cause of death and ischemic time, the recipient's race, age, original disease, infection, systemic cerebro-vascular disease, whether or not they were on life support, renal function etc, significantly impacted on graft survival. Immunological factors, such as previous transfusion, previous transplantation, HLA mismatches, sensitization status, rejection episodes before discharge or within one year after transplant, were associated with lower graft survival rates. In conclusion, in order to achieve the best possible outcome for heart transplant patients, we must first find the most suitable candidate for an available donated heart; secondly, we must optimize immunosuppressive regimens and other medical and surgical therapies to prevent graft rejection and transplant-related complications.
捐赠心脏的有限供应不足以满足越来越多心脏移植候选者的需求。因此,为每个捐赠心脏找到最佳受者以实现最佳的移植物存活和患者生存很重要。我们调查了美国心脏移植的结果及其影响因素。我们提供了1988年1月至2004年10月向器官共享联合网络/美国器官分配系统登记处报告的36277例心脏移植的相关信息。在过去14年中,每年的移植数量在2057至2363例之间,自1990年以来没有增加。成年受者的1年和5年移植物存活率逐渐提高,分别达到了87%和72%。非免疫因素,如供者死亡情况、死因和缺血时间、受者的种族、年龄、原发病、感染、全身性脑血管疾病、是否使用生命支持、肾功能等,对移植物存活有显著影响。免疫因素,如既往输血、既往移植、HLA错配、致敏状态、出院前或移植后一年内的排斥反应,与较低的移植物存活率相关。总之,为了使心脏移植患者获得尽可能好的结果,我们必须首先为可用的捐赠心脏找到最合适的候选者;其次,我们必须优化免疫抑制方案以及其他药物和手术治疗,以预防移植物排斥和移植相关并发症。